XM does not provide services to residents of the United States of America.
C
C

Cellnex

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Expect more telco M&A ahead in Europe, MS says

BUZZ-Expect more telco M&A ahead in Europe, MS says ** After an action packed year so far in European telcos M&A space, Morgan Stanley says there's likely still more to come ** "Whilst our upbeat view on the sector is based on fundamentals, we continue to think M&A could skew the sector's risk reward upward," MS says in a July 3 note ** The broker
B
B
C
D
E
K
O
P
S
T
T
V
T

ASMI, EasyJet, Kooth

EUROPE RESEARCH ROUNDUP-ASMI, EasyJet, Kooth July 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including ASMI, EasyJet and Kooth, on Wednesday. HIGHLIGHTS * ASMI ASMI.AS : Jefferies raises target price to EUR 880 from EUR 780 * B.P. Marsh & Partners Plc BPM.L : Jefferies raises target price to 625p from 560p * EasyJet EZJ.L : JP Morgan cuts target price to 640p from 670p * Kooth Plc KOO.L : Berenberg initiates coverage with buy rating;
3
A
A
A
A
B
B
C
C
C
D
D
E
E
E
F
K
A
H
A
A
D

Spanish stocks - Factors to watch on July 3

Spanish stocks - Factors to watch on July 3 July 3 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy: GRIFOLS GRLS.MC Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its units.
A
C
G
S

Cellnex CEO: 2024 Will Be In Line With Targets Or A Little Better

BRIEF-Cellnex CEO: 2024 Will Be In Line With Targets Or A Little Better July 2 (Reuters) - Cellnex Telecom's CLNX.MC Chief Executive Marco Patuano tells a conference in Barcelona: 2024 WILL BE IN LINE WITH TARGETS OR A LITTLE BETTER Source text for Eikon: [ID:] Further company coverage: CLNX.MC
C

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.